President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...